GPEx® Lightning Technology
Summary: Catalent’s GPEx® Lightning platform transforms cell line development for next-generation biologics, enabling faster and more efficient production of stable, high-yield expression systems. With over 100 docking sites in transcriptionally active regions, this technology ensures seamless integration of your gene of interest (GOI), achieving high-titer expression and consistent performance across diverse protein modalities, including multispecifics and complex proteins.
GPEx® Lightning offers scalability and stability throughout the development process, from gene construct development to GMP manufacturing, cutting development timelines by 6-12 weeks. The platform supports rapid scale-up, minimal optimization, and reliable transitions from research to clinical and commercial stages. Trusted by biopharma leaders for its proven track record, Catalent’s GPEx® Lightning is the ideal solution for accelerating time-to-market and bringing innovative biologics to patients faster.